Annotation Detail
Information
- Associated Genes
- TP53
- Associated Variants
-
TP53 DELETERIOUS MUTATION
TP53 DELETERIOUS MUTATION - Associated Disease
- breast cancer
- Source Database
- CIViC Evidence
- Description
- In this preclinical study, MMTV-Wnt1 mammary tumors with mutant TP53 showed a better clinical response to chemotherapy (doxorubicin) than TP53 wild-type tumors. This was mediated by wild-type TP53-induced cell-arrest under chemotherapy even in the context of heterozygous TP53 point mutations or absence of p21. Thus the status of both TP53 alleles should be assessed because even one copy of wild-type TP53 may contribute to poor response to chemotherapy.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/851
- Gene URL
- https://civic.genome.wustl.edu/links/genes/45
- Variant URL
- https://civic.genome.wustl.edu/links/variants/222
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Breast Cancer
- Evidence Direction
- Supports
- Drug
- Doxorubicin
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22698404
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Doxorubicin | Sensitivity | true |